To validate these findings, we studied the expression of 22 selected genes differentially expressed (11 up and 11 down) between the two groups of gliomas in an independent data set of 16 gliomas (8 gliomas with EGFR amplification and 8 gliomas with 1p19q codeletion). The gene discussed is EGFR; the disease is central nervous system cancer.